Aclaris Therapeutics, Inc.
ACRS
$4.88
-$0.07-1.41%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 54.13% | -60.75% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 54.13% | -60.75% | |||
| Cost of Revenue | -3.37% | 16.64% | |||
| Gross Profit | 7.81% | -37.61% | |||
| SG&A Expenses | 20.93% | 14.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.37% | 16.12% | |||
| Operating Income | 0.64% | -31.00% | |||
| Income Before Tax | -0.15% | -35.45% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -0.15% | -35.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -0.15% | -35.45% | |||
| EBIT | 0.64% | -31.00% | |||
| EBITDA | 0.60% | -31.02% | |||
| EPS Basic | 4.65% | -35.40% | |||
| Normalized Basic EPS | 2.63% | -33.51% | |||
| EPS Diluted | 4.65% | -35.40% | |||
| Normalized Diluted EPS | 2.63% | -33.51% | |||
| Average Basic Shares Outstanding | 5.01% | 0.04% | |||
| Average Diluted Shares Outstanding | 5.01% | 0.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||